SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ENTYVIO

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since 2014 (IV) and recently launched subcutaneously (Entyvio Pen). Biosimilar entry is the main future risk, with Alvotech's AVT16 BLA accepted for FDA review as of June 2026 and AVT80 BLA accepted in August 2026.
Why 4/10
ENTYVIO is already approved and marketed; there is no pending PDUFA, FDA advisory committee, or registrational-trial readout for this drug in the next 12 months. All recent catalysts (Phase 4 VERDICT data, raised guidance) have already occurred. The next hard catalyst would be a biosimilar approval decision or patent litigation ruling, neither of which has a confirmed date, so the binary event risk is minimal in the near term.
Actionable Insight NEUTRAL

With the VERDICT Phase 4 data already released (October 19, 2026) and no upcoming FDA decision or pivotal readout for ENTYVIO itself, the next catalysts for TAK shareholders are the biosimilar patent litigation outcomes against Alvotech, Polpharma, and Samsung, plus quarterly sales trends. Litigation timelines are uncertain, making the near-term binary low for this specific drug.

Price Chart

Loading chart...

Executive Summary

ENTYVIO (vedolizumab) is Takeda's blockbuster biologic for ulcerative colitis and Crohn's disease, first approved by the FDA in 2014 and now available in both intravenous and subcutaneous (Entyvio Pen) formulations. It is a key growth driver for Takeda, a diversified global pharma company. In October 2026, positive Phase 4 VERDICT data showed that treating to a disease-clearance endpoint reduced UC complication risk by about 67%, boosting the drug's clinical differentiation. The main overhang is biosimilar competition: Alvotech has two BLAs (AVT16 for IV, AVT80 for SC) under FDA review, and Takeda has filed patent lawsuits against Alvotech, Polpharma, and faces IP challenges from Samsung. With no upcoming regulatory decision for ENTYVIO itself, the drug's commercial trajectory depends on share protection from patents, market growth, and the pace of biosimilar entry.

How It Works

ENTYVIO is a biologic (monoclonal antibody) that works like a gut-specific traffic cop. It binds to a specific protein on immune cells (alpha4-beta7 integrin) that would normally allow those cells to travel from the bloodstream into the gut tissue. By blocking this interaction, ENTYVIO prevents inflammatory white blood cells from entering the gut lining, reducing inflammation in ulcerative colitis and Crohn's disease while largely leaving the rest of the immune system alone.

Trial Status

Phase 4 VERDICT trial results announced October 19, 2026, showed a 67% relative risk reduction in UC complications with a disease-clearance treatment strategy. Pediatric Phase 3 and Phase 2 studies have completed.

The Two-Sided Case

▲ Bull Case3
Positive Phase 4 VERDICT data (October 19, 2026) showed that treating UC patients to achieve disease clearance with ENTYVIO reduced the risk of disease-related complications by approximately 67% (HR 0.33) compared to targeting symptomatic remission alone, which could strengthen the drug's clinical positioning and potentially expand utilization.
Entyvio remains a multi-billion-dollar blockbuster and key growth driver for Takeda. The company raised its FY2026 revenue guidance to JPY 4,700 billion (from JPY 4,640 billion) on October 29, 2026, partly reflecting strong performance from its Growth & Launch Products including ENTYVIO.
Institutional accumulation: Major funds including FMR LLC (Fidelity) added 34.9% to their TAK position in Q2 2026, and Qube Research & Technologies opened a new ~$35M position, while the analyst consensus shows 14 buy/strong-buy ratings vs 7 holds and zero sells.
▼ Bear Case3
Multiple biosimilar threats: Alvotech's AVT16 (IV) and AVT80 (SC) biosimilar BLAs were accepted for FDA review in 2026, and Alvotech reported positive Phase 1 PK data for AVT80 in February 2026. Takeda has filed BPCIA patent lawsuits against Alvotech (September 2026), Polpharma Biologics (August 2026), and Samsung is also challenging Entyvio IP, but the patent thicket can only delay, not prevent, biosimilar entry.
Insider selling: Takeda executives including CEO Julie Kim, R&D President Andrew Plump, and several other officers sold shares in August-September 2026 at prices around $17-18.50, with the CEO selling ~$1.5M worth on August 10, 2026.
Competitive pressure from newer oral therapies (JAK inhibitors like Rinvoq, S1P receptor modulators, and Gilead's emerging emvistegrast) could erode Entyvio's positioning in the IBD market over time.

Upcoming Catalysts

  • Biosimilar patent litigation outcomes: BPCIA lawsuits against Alvotech and Polpharma Biologics
  • FDA review decisions on Alvotech's AVT16 (IV) and AVT80 (SC) biosimilar BLAs
  • Quarterly ENTYVIO sales performance in Takeda earnings reports

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 12

Hover a chip for the title
1 rttnews.com2 rttnews.com3 jdsupra.com4 jdsupra.com5 markets.financialcontent.com6 nasdaq.com7 law360.com8 marketwatch.com9 seekingalpha.com10 en.wikipedia.org11 globaldata.com12 marketscreener.com